U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H10O5
Molecular Weight 198.1727
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SYRINGIC ACID

SMILES

COC1=CC(=CC(OC)=C1O)C(O)=O

InChI

InChIKey=JMSVCTWVEWCHDZ-UHFFFAOYSA-N
InChI=1S/C9H10O5/c1-13-6-3-5(9(11)12)4-7(14-2)8(6)10/h3-4,10H,1-2H3,(H,11,12)

HIDE SMILES / InChI

Molecular Formula C9H10O5
Molecular Weight 198.1727
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Syringic acid (SYRA) is a potential antioxidant used in traditional Chinese medicine and is an emerging nutraceutical. Current reports claim its potential anti-angiogenic, anti-glycating, anti-hyperglycaemic, neuroprotective, and memory-enhancing properties in various animal models. Syringic acid (SA) possesses anti-obesity, anti-inflammatory and anti-steatotic effects via the regulation of lipid metabolic and inflammatory genes. SA is likely to be a new natural therapeutic agent for obesity or non-alcoholic liver disease. Syringic acid reduces oxidative stress and axonal degeneration in rat sciatic nerve after ischemia/reperfusion injury. Syringic acid may play a role in the treatment of peripheral nerve injuries due to ischemia/reperfusion.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
3.19 µM [Ki]
4.15 µM [Ki]
6.34 µM [Ki]
7.55 µM [Ki]
0.107 mM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Hypertension treatment: Rats were treated with different doses of Syringic acid (SA) (25, 50, and 100 mg/kg body weight (b.w.)). The protective effect at the dose of the three tested doses (25, 50, and 100 mg/kg) of SA at a dose of 50 mg/kg b.w. exerts optimum protection.
Route of Administration: Oral
In Vitro Use Guide
The results of 3-(4,5-dimethylthiazol‑2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays showed that pre-treatment with SA (0.1, 1, 10, and 20 uM) attenuated OGD/R-induced neuronal injury in a dose-dependent manner, with evidence of increased cell viability and decreased LDH leakage in cultured hippocampal neuronal cells..
Substance Class Chemical
Record UNII
E390O181H5
Record Status Validated (UNII)
Record Version